A new large-scale study suggests transcranial magnetic stimulation may be an option for individuals who do not respond to conventional care for depression.
Transcranial magnetic stimulation (TMS), is a non-invasive technique that excites neurons in the brain by magnetic pulses introduced through the scalp. The modality has generally mild side-effects and is well tolerated by patients.
Prior research studies on smaller groups of individuals were inconclusive on the benefits of TMS.
Study co-author Dr. Philip Janicak, professor of Psychiatry at Rush University Medical Center, says the treatment may be an option for patients with major depression who have not responded to conventional antidepressant medications.
Current antidepressant therapies are not beneficial for at least a third of depressed individuals, leaving many with a lack of adequate treatment options. This study will be published in the December 1st issue of Biological Psychiatry.
The authors present the results from the first large scale, multi-center, double-blind, sham-controlled study of TMS as a treatment for people with depression who had not responded to prior antidepressants and who were not taking antidepressant medications during the study.
After four to six weeks of active or sham TMS, response and remission rates with active TMS were approximately twice those of sham.
This study was also associated with a low dropout rate, due to generally mild side effects, indicating that the treatment was well-tolerated by patients.
Dr. John P. O’Reardon, the corresponding author on this project and associate professor of Psychiatry at the University of Pennsylvania, explains, “These results indicate that TMS provides a novel and attractive treatment option for patients with major depression who have not responded to conventional antidepressant medications.”
Dr. John H. Krystal, editor of Biological Psychiatry, highlights the significance of this article’s findings.
“This study provides new support for the efficacy of TMS as a ‘stand alone’ treatment for depression. This finding could be particularly important for patients who do not tolerate antidepressant medications, for whom they are not safe, or who have not benefited from other alternative treatments.”
O’Reardon adds, “As indicated by recent large scale, government-sponsored, studies of existing treatment options for major depression conducted by the National Institute of Health (the STAR-D reports), there is a great need to develop new effective treatments for patients, especially those not benefiting from first line interventions. The results of this study indicate that TMS offers new hope to patients in this regard.”
Source: Rush University Medical Center